KRW 18280.0
(-0.33%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 4.16 Billion KRW | -90.24% |
2022 | 42.67 Billion KRW | 6.71% |
2021 | 39.98 Billion KRW | 454.23% |
2020 | 7.21 Billion KRW | 924.56% |
2019 | 704.2 Million KRW | 0.0% |
2018 | - KRW | 0.0% |
2017 | - KRW | 0.0% |
2016 | - KRW | 0.0% |
2015 | - KRW | 0.0% |
2014 | - KRW | 0.0% |
2013 | - KRW | 0.0% |
2012 | - KRW | 0.0% |
2011 | - KRW | -100.0% |
2010 | 3 Billion KRW | 0.0% |
2009 | - KRW | -100.0% |
2008 | 9 Billion KRW | 50.0% |
2007 | 6 Billion KRW | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 2.08 Billion KRW | -50.0% |
2024 Q2 | - KRW | -100.0% |
2023 Q4 | 4.16 Billion KRW | -33.33% |
2023 Q1 | 40.6 Billion KRW | -4.45% |
2023 Q2 | 8.51 Billion KRW | -79.02% |
2023 FY | 4.16 Billion KRW | -90.24% |
2023 Q3 | 6.24 Billion KRW | -26.64% |
2022 Q4 | 42.49 Billion KRW | -5.16% |
2022 Q2 | 44.98 Billion KRW | 4.38% |
2022 Q1 | 43.09 Billion KRW | 7.77% |
2022 FY | 42.67 Billion KRW | 6.71% |
2022 Q3 | 44.81 Billion KRW | -0.37% |
2021 Q3 | 33.22 Billion KRW | 49.02% |
2021 Q2 | 22.29 Billion KRW | 33.62% |
2021 FY | 39.98 Billion KRW | 454.23% |
2021 Q1 | 16.68 Billion KRW | 131.28% |
2021 Q4 | 39.98 Billion KRW | 20.35% |
2020 FY | 7.21 Billion KRW | 924.56% |
2020 Q3 | 7.08 Billion KRW | 1.95% |
2020 Q4 | 7.21 Billion KRW | 1.87% |
2020 Q1 | 646.91 Million KRW | -8.14% |
2020 Q2 | 6.94 Billion KRW | 973.83% |
2019 Q4 | 704.2 Million KRW | -21.42% |
2019 Q3 | 896.13 Million KRW | 812.04% |
2019 FY | 704.2 Million KRW | 0.0% |
2019 Q1 | 125.56 Million KRW | 0.0% |
2019 Q2 | 98.25 Million KRW | -21.75% |
2018 Q1 | - KRW | 0.0% |
2018 Q3 | - KRW | 0.0% |
2018 Q2 | - KRW | 0.0% |
2018 Q4 | - KRW | 0.0% |
2018 FY | - KRW | 0.0% |
2017 Q3 | - KRW | 0.0% |
2017 Q2 | - KRW | 0.0% |
2017 Q1 | - KRW | 0.0% |
2017 FY | - KRW | 0.0% |
2017 Q4 | - KRW | 0.0% |
2016 Q1 | - KRW | 0.0% |
2016 Q3 | - KRW | 0.0% |
2016 Q2 | - KRW | 0.0% |
2016 Q4 | - KRW | 0.0% |
2016 FY | - KRW | 0.0% |
2015 FY | - KRW | 0.0% |
2015 Q4 | - KRW | 0.0% |
2015 Q3 | - KRW | 0.0% |
2015 Q2 | - KRW | 0.0% |
2015 Q1 | - KRW | 0.0% |
2014 Q2 | - KRW | 0.0% |
2014 Q3 | - KRW | 0.0% |
2014 FY | - KRW | 0.0% |
2014 Q4 | - KRW | 0.0% |
2014 Q1 | - KRW | 0.0% |
2013 Q3 | - KRW | 0.0% |
2013 Q4 | - KRW | 0.0% |
2013 FY | - KRW | 0.0% |
2013 Q1 | - KRW | 0.0% |
2013 Q2 | - KRW | 0.0% |
2012 Q2 | - KRW | 0.0% |
2012 Q1 | - KRW | 0.0% |
2012 FY | - KRW | 0.0% |
2012 Q4 | - KRW | 0.0% |
2012 Q3 | - KRW | 0.0% |
2011 Q3 | - KRW | 0.0% |
2011 Q4 | - KRW | 0.0% |
2011 FY | - KRW | -100.0% |
2011 Q1 | 3 Billion KRW | 0.0% |
2011 Q2 | - KRW | -100.0% |
2010 Q4 | 3 Billion KRW | 0.0% |
2010 Q3 | 3 Billion KRW | 0.0% |
2010 FY | 3 Billion KRW | 0.0% |
2010 Q1 | - KRW | 0.0% |
2010 Q2 | 3 Billion KRW | 0.0% |
2009 Q2 | 3 Billion KRW | -78.57% |
2009 FY | - KRW | -100.0% |
2009 Q4 | - KRW | -100.0% |
2009 Q3 | 3 Billion KRW | 0.0% |
2009 Q1 | 14 Billion KRW | 55.56% |
2008 Q4 | 9 Billion KRW | 50.0% |
2008 Q2 | 6 Billion KRW | 0.0% |
2008 Q1 | 6 Billion KRW | 0.0% |
2008 Q3 | 6 Billion KRW | 0.0% |
2008 FY | 9 Billion KRW | 50.0% |
2007 Q1 | 11.01 Billion KRW | 0.0% |
2007 FY | 6 Billion KRW | 0.0% |
2007 Q4 | 6 Billion KRW | -57.18% |
2007 Q3 | 14.01 Billion KRW | 0.0% |
2007 Q2 | 14.01 Billion KRW | 27.24% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Yuyu Pharma, Inc. | 13.64 Billion KRW | 69.453% |
Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 97.938% |
Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 86.054% |
HANDOK Inc. | 123.78 Billion KRW | 96.634% |
Kukje Pharma Co., Ltd. | 475.74 Million KRW | -775.818% |
Yuhan Corporation | 60.23 Billion KRW | 93.083% |
Dong-A ST Co., Ltd. | 161.99 Billion KRW | 97.428% |
SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -3992.251% |
Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 94.92% |
Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -605.84% |
Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 31.13% |
Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | 77.505% |
MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | 66.89% |
Hana Pharm Co., Ltd. | 1.59 Billion KRW | -160.603% |
Yuyu Pharma, Inc. | 13.64 Billion KRW | 69.453% |
Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -3381.531% |
REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 96.556% |
Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 86.979% |
JW Holdings Corporation | 20.65 Billion KRW | 79.83% |
Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | 71.895% |
Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 86.111% |
JW Pharmaceutical Corporation | 30 Billion KRW | 86.111% |
Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -1802.914% |
Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -617.587% |
Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 91.594% |
Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | 6.41% |
Yuyu Pharma, Inc. | 13.64 Billion KRW | 69.453% |
Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 78.102% |
Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 95.54% |
JW Pharmaceutical Corporation | 30 Billion KRW | 86.111% |
Yuhan Corporation | 60.23 Billion KRW | 93.083% |
Jeil Pharma Holdings Inc | 10.5 Billion KRW | 60.318% |
Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 89.681% |
Suheung Co., Ltd. | 74 Billion KRW | 94.37% |
JW Pharmaceutical Corporation | 30 Billion KRW | 86.111% |
Korea United Pharm Inc. | 10.96 Billion KRW | 61.992% |
CKD Bio Corp. | 69.43 Billion KRW | 93.999% |
Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 87.949% |
Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | 74.165% |
Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -1256.963% |
Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -1802.914% |
Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 94.222% |
Boryung Corporation | 151.7 Billion KRW | 97.254% |
Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 94.694% |
Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 31.13% |
JW Lifescience Corporation | 168 Million KRW | -2380.143% |